Posted by Michael Wonder on 30 May 2019
Health economic assessment of Luxturna in the treatment of visual impairment caused by hereditary eye disease
29 May 2019 - TLV has produced a health economic knowledge base for the region for the drug Luxturna (voretigene neparvovec). Luxturna is used to treat visual impairment caused by hereditary eye diseases due to mutation in the RPE65 gene.
TLV assesses the severity of the disease as high. Patients with hereditary eye diseases due to mutation in the RPE65 gene often have a severe visual impairment in their childhood or adolescence. The disease leads to total blindness. There are currently no treatments with proven efficacy in the current disease state.
TLV believes that the treatment effect of Luxturna is clinically relevant. In the clinical Phase III trials, most patients treated with Luxturna have improved in joint vision, especially in low-light environments. The effect of the drug has been shown to persist for at least three years. However, there is uncertainty about the effect of treatment in the longer term.
TLV estimates that the cost per won quality adjusted life year for Luxturna in comparison with the best supportive treatment lies in a range between 1.8 and 3 million SEK.
